Results 161 to 170 of about 5,279 (205)

New Data on Paxlovid Reported

AJN, American Journal of Nursing, 2022
According to this study: In a phase 2/phase 3 study of Paxlovid use in patients at standard risk for developing severe COVID-19, the primary end point of self-reported sustained alleviation of all symptoms for four consecutive days wasn't met.A nonsignificant ...
openaire   +2 more sources

Barriers to Worldwide Access for Paxlovid, a New Treatment for COVID-19.

Open Forum Infectious Diseases, 2022
Pfizer and the Medicines Patent Pool (MPP) have reached a voluntary licensing agreement for Paxlovid (nirmatrelvir+ritonavir), a novel antiviral for coronavirus disease 2019 (COVID-19) taken orally in the first 5 days from symptom onset.
Andrew M Hill, Junzheng Wang, Doctor Toby Pepperrell   +2 more
exaly   +2 more sources

Effectiveness of Paxlovid - a review

2023
Abstract Paxlovid is an oral treatment for mild to moderate COVID-19 cases with a high risk for severe course of the disease. For this review, we have performed a comprehensive literature review. We present a summary of currently available data on Paxlovid’s ability to reduce the risk of progressing to a severe disease state.
Sydney Paltra, Tim Conrad
openaire   +1 more source

Optimizing the use of Paxlovid in clinical practice

Drugs of Today, 2022
On December 22, 2021, the United States Food and Drug Administration (FDA) issued an emergency use authorization (EUA) for nirmatrelvir/ritonavir (Paxlovid) for the treatment of mild to moderate coronavirus disease 2019 (COVID-19). The drug is authorized for use in patients 12 years of age and older weighing at least 40 kg who have tested positive for ...
openaire   +2 more sources

Paxlovid as a potential treatment for long COVID

Expert Opinion on Pharmacotherapy, 2023
On 31 July 2023, the United States Department of Health and Human Services announced the formation of the Office of Long COVID Research and Practice and the United States National Institutes of Health opened enrollment for RECOVER-Vital, a randomized study to evaluate new treatment options for long Coronavirus (long COVID).The RECOVER Initiative is a ...
openaire   +2 more sources

Paxlovid-Induced SIADH

American Journal of Respiratory and Critical Care Medicine
Abstract Introduction:Hyponatremia, defined as serum sodium levels <135 mEq/L, is one of the most common electrolyte abnormality among hospitalized patients, with Syndrome of Inappropriate Antidiuretic Hormone Secretion (SIADH) as a frequent cause. The diagnosis can be challenging due to its complex pathophysiology and multiple
S. Goyal, V. Vedantam
openaire   +1 more source

Paxlovid‐associated dysgeusia

Oral Diseases, 2022
John K. Brooks, Julia H. Song, Ahmed S. Sultan   +2 more
openaire   +2 more sources

A tale of two drugs: Molnupiravir and Paxlovid

Mutation Research - Reviews in Mutation Research
The orally administered antiviral drug Lagevrio or molnupiravir (MOV) and the combination antiviral drug nirmatrelvir/ritonavir or Paxlovid (PAX) have been shown to reduce the likelihood of hospitalization and death for high-risk patients with COVID-19.
Michael D. Waters, Stafford G. Warren
openaire   +2 more sources

Epidemiological Study of the Effectiveness of Paxlovid

Clinical Infectious Diseases, 2022
Hui-Yuan Chen, Renin Chang, James Cheng-Chung Wei   +2 more
openaire   +2 more sources

Nirmatrelvir-Ritonavir (Paxlovid)

Canadian Journal of Health Technologies
CADTH reimbursement reviews are comprehensive assessments of the clinical effectiveness and cost-effectiveness, as well as patient and clinician perspectives, of a drug or drug class. The assessments inform non-binding recommendations that help guide the reimbursement decisions of Canada's federal, provincial, and territorial governments, with the ...
openaire   +1 more source